NVS
Price
$126.38
Change
-$0.09 (-0.07%)
Updated
Aug 29, 04:10 PM (EDT)
Capitalization
244.54B
60 days until earnings call
RHHBY
Price
$40.88
Change
-$0.03 (-0.07%)
Updated
Aug 28 closing price
Capitalization
260.55B
55 days until earnings call
Interact to see
Advertisement

NVS vs RHHBY

Header iconNVS vs RHHBY Comparison
Open Charts NVS vs RHHBYBanner chart's image
Novartis AG
Price$126.38
Change-$0.09 (-0.07%)
Volume$300
Capitalization244.54B
Roche Holding
Price$40.88
Change-$0.03 (-0.07%)
Volume$2.87M
Capitalization260.55B
NVS vs RHHBY Comparison Chart in %
Loading...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVS vs. RHHBY commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a Buy and RHHBY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (NVS: $126.47 vs. RHHBY: $40.88)
Brand notoriety: NVS and RHHBY are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 42% vs. RHHBY: 212%
Market capitalization -- NVS: $244.54B vs. RHHBY: $260.55B
NVS [@Pharmaceuticals: Major] is valued at $244.54B. RHHBY’s [@Pharmaceuticals: Major] market capitalization is $260.55B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 2 FA rating(s) are green whileRHHBY’s FA Score has 1 green FA rating(s).

  • NVS’s FA Score: 2 green, 3 red.
  • RHHBY’s FA Score: 1 green, 4 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHBY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 5 TA indicator(s) are bullish while RHHBY’s TA Score has 7 bullish TA indicator(s).

  • NVS’s TA Score: 5 bullish, 5 bearish.
  • RHHBY’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RHHBY is a better buy in the short-term than NVS.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а -0.28% price change this week, while RHHBY (@Pharmaceuticals: Major) price change was +1.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

NVS is expected to report earnings on Oct 28, 2025.

RHHBY is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHBY($261B) has a higher market cap than NVS($245B). RHHBY has higher P/E ratio than NVS: RHHBY (22.39) vs NVS (18.44). NVS YTD gains are higher at: 34.645 vs. RHHBY (21.099). NVS has higher annual earnings (EBITDA): 22.7B vs. RHHBY (18B). RHHBY has more cash in the bank: 12B vs. NVS (7B). NVS (32.6B) and RHHBY (33B) have identical debt. RHHBY has higher revenues than NVS: RHHBY (63.5B) vs NVS (55.2B).
NVSRHHBYNVS / RHHBY
Capitalization245B261B94%
EBITDA22.7B18B126%
Gain YTD34.64521.099164%
P/E Ratio18.4422.3982%
Revenue55.2B63.5B87%
Total Cash7B12B58%
Total Debt32.6B33B99%
FUNDAMENTALS RATINGS
NVS vs RHHBY: Fundamental Ratings
NVS
RHHBY
OUTLOOK RATING
1..100
2514
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
12
Undervalued
PROFIT vs RISK RATING
1..100
1384
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4656
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RHHBY's Valuation (12) in the null industry is in the same range as NVS (14) in the Pharmaceuticals Major industry. This means that RHHBY’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHBY (84) in the null industry. This means that NVS’s stock grew significantly faster than RHHBY’s over the last 12 months.

NVS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as RHHBY (100) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as RHHBY (56) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

NVS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RHHBY (100) in the null industry. This means that NVS’s stock grew similarly to RHHBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHBY
RSI
ODDS (%)
Bearish Trend 2 days ago
52%
Bullish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
40%
Bearish Trend 2 days ago
53%
Momentum
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
47%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
44%
Bullish Trend 2 days ago
48%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 3 days ago
49%
Bullish Trend 3 days ago
50%
Declines
ODDS (%)
Bearish Trend 24 days ago
45%
Bearish Trend 19 days ago
46%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
39%
Bearish Trend 2 days ago
42%
Aroon
ODDS (%)
Bearish Trend 2 days ago
31%
Bullish Trend 2 days ago
44%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RHHBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HWH1.450.04
+2.48%
HWH International Inc.
HAL22.630.33
+1.48%
Halliburton Company
CRNX30.650.25
+0.82%
Crinetics Pharmaceuticals
AIOT4.66-0.14
-2.92%
PowerFleet Inc.
UCL3.16-0.28
-8.14%
uCloudlink Group

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.33%
GSK - NVS
68%
Closely correlated
-1.18%
AZN - NVS
61%
Loosely correlated
+0.08%
PFE - NVS
57%
Loosely correlated
-1.87%
JNJ - NVS
54%
Loosely correlated
-0.76%
SNY - NVS
54%
Loosely correlated
-0.34%
More

RHHBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHBY has been loosely correlated with RHHVF. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHBY jumps, then RHHVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHBY
1D Price
Change %
RHHBY100%
-0.07%
RHHVF - RHHBY
65%
Loosely correlated
-1.80%
NVS - RHHBY
37%
Loosely correlated
-0.33%
JNJ - RHHBY
37%
Loosely correlated
-0.76%
RHHBF - RHHBY
32%
Poorly correlated
-3.04%
BMY - RHHBY
28%
Poorly correlated
-1.57%
More